Delving into the Latest Updates on Mobenakin with Synapse

Overview

Basic Info

Drug Type

Interleukins

Synonyms

Interleukin-1 beta mutein

Target

IL-1β

Mechanism

IL-1β modulators(Interleukin-1 beta modulators)

Therapeutic Areas

NeoplasmsImmune System DiseasesHemic and Lymphatic Diseases+ [2]

Active Indication-

Inactive Indication

GliomaLymphomaNeoplasms+ [1]

Originator Organization

Chiron Corp.

Active Organization-

Inactive Organization

Chiron Corp.Otsuka Holdings Co., Ltd.

Otsuka Pharmaceutical Co., Ltd.

Drug Highest PhaseDiscontinuedNDA/BLA

First Approval Date-

Regulation-

Login to view timeline

Gene Sequence

Sequence Code 28795085

Source: *****

Ten patients with advanced urologic cancers who were scheduled to receive at least two courses of chemotherapy were enrolled in this trial. Fifty thousand units of recombinant human interleukin-1 (IL-1) beta analogue OCT-43 (Otsuka Pharmaceutical Co., Ltd., Tokyo, Japan) was administered subcutaneously only once or twice when severe neutropenia (less than 500/microliters) continued for 2 consecutive days. In eight patients, OCT-43 was not injected in the first course of chemotherapy as a control, but was injected in the second course. The durations of leukocytopenia (less than 2000/microliters) and neutropenia (less than 1000/microliters) were significantly shortened in the second course compared with those in the first course in those eight patients. Recovery of neutrophil number from the lowest number was also significantly faster in the second course. Thus, OCT-43 was considered to have hematopoietic activities. However, single or double injection of OCT-43 did not affect the numbers of eosinophilic or basophilic granulocytes, monocytes, or platelets. Adverse effects associated with OCT-43 injections were high fever and chills, but they were controlled by indomethacin.

100 Deals associated with Mobenakin

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Glioma	NDA/BLA	JP	Otsuka Pharmaceutical Co., Ltd.	-
Glioma	NDA/BLA	-	Chiron Corp.	-
Glioma	NDA/BLA	-	Otsuka Holdings Co., Ltd.	-
Lymphoma	NDA/BLA	JP	Otsuka Pharmaceutical Co., Ltd.	-
Lymphoma	NDA/BLA	-	Otsuka Holdings Co., Ltd.	-
Lymphoma	NDA/BLA	-	Chiron Corp.	-
Neoplasms	NDA/BLA	US	Chiron Corp.	-
Urogenital Neoplasms	NDA/BLA	JP	Otsuka Pharmaceutical Co., Ltd.	-
Urogenital Neoplasms	NDA/BLA	-	Otsuka Holdings Co., Ltd.	-
Urogenital Neoplasms	NDA/BLA	-	Chiron Corp.	-